EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Discovery of a Pyrazine-2-Carboxamide Derivative as a Potent Plasmodium falciparum Inhibitor with Potential for Single-Dose Cure

Vanessa M Marx iD, Anne-Catherine Mata, Fumiaki Yokokawa iD, Thomas Kirrane, Richard Huang, Suresh B Lakshminarayana, Jay Prakash Jain, Judith Straimer, W Armand Guiguemde iD, Luying Pei, Upendra Kulkarni, Christopher J Thompson und 35 weitere

Journal of Medicinal Chemistry · 12.11.2026 · 69 (21) · 25712-25725

DOI: 10.1021/acs.jmedchem.6c01710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 19.10.2026. Verfasst von Vanessa M Marx und 46 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Biomedical Research, Novartis, Emeryville, California94608, United States. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Pyrazines, Drug Discovery. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, National Institute of Allergy and Infectious Diseases, Medicines for Malaria Venture.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malaria remains a major cause of morbidity and mortality, particularly among young children, in endemic regions such as sub-Saharan Africa and Southeast Asia. Moreover, the emerging resistance of Plasmodium parasites to front-line therapeutics underscores the need for new blood-stage antimalarial drugs. Utilizing a Plasmodium falciparum (Pf) growth inhibition assay, we identified a novel pyrazine-2-carboxamide series. Lead optimization improved anti-plasmodial potency, metabolic stability, and reduced CYP2D6 inhibition risk, leading to the selection of IWY357 (1). A single dose of 100 mg per kg (mpk) is fully curative in a Pf-humanized severe combined immunodeficient mouse model (TADhuMouse®-Pfalc), and IWY357 (1) also exhibits a high barrier to resistance in drug selection studies. Given the significant potential to provide a curative therapy for uncomplicated malaria with short dosing regimens, either alone or in combination, IWY357 (1) was progressed through GLP toxicology studies into phase 1 clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsPyrazinesDrug DiscoveryMalaria, FalciparumAnimalsHumansMiceStructure-Activity RelationshipMice, SCID

Stichwörter der Autor:innen

antimalarialblood stagefalciparuminhibitormalariaphenotypicplasmodiumsingle dosevivax

Substanzen

AntimalarialsPyrazines

Autor:innen und Institutionen

  • Global Discovery Chemistry, Biomedical Research, Novartis, Emeryville, California94608, United States.
  • Global Health, Biomedical Research, Novartis, Emeryville, California94608, United States.
  • Global Drug Development, Novartis Pharmaceuticals, Cambridge, Massachusetts02139, United States.
  • Translational Medicine,, Biomedical Research, Novartis, Cambridge, Massachusetts02139, United States.
  • The Art of Discovery, Astondo Bidea, Bizkaia, Basque Country48160, Spain.
  • Parasite Chemotherapie Group, Swiss TPH, Allschwil4123, Switzerland.

ORCID-Profile: Vanessa M Marx, Fumiaki Yokokawa, W Armand Guiguemde, Johanna M Jansen, Eric J Martin, Valery R Polyakov, Anna Caroline Campos Aguiar, Kyra A Schindler

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • National Institute of Allergy and Infectious Diseases
  • Medicines for Malaria Venture
  • Fundação de Amparo à Pesquisa do Estado de São Paulo

Zitieren

APA

Marx, V. M., Mata, A. C., Yokokawa, F., Kirrane, T., Huang, R., Lakshminarayana, S. B., Jain, J. P., Straimer, J., Guiguemde, W. A., Pei, L., Kulkarni, U., Thompson, C. J., Jansen, J. M., Lee, P. S., Martin, E. J., Polyakov, V. R., Blaquiere, N., Burckle, A., Waldron, G., …, & Sarko, C. R. (2026). Discovery of a Pyrazine-2-Carboxamide Derivative as a Potent Plasmodium falciparum Inhibitor with Potential for Single-Dose Cure. Journal of Medicinal Chemistry, 69(21), 25712-25725. https://doi.org/10.1021/acs.jmedchem.6c01710

Vancouver

Marx VM, Mata AC, Yokokawa F, Kirrane T, Huang R, Lakshminarayana SB, et al. Discovery of a Pyrazine-2-Carboxamide Derivative as a Potent Plasmodium falciparum Inhibitor with Potential for Single-Dose Cure. Journal of Medicinal Chemistry. 2026;69(21):25712-25725. doi:10.1021/acs.jmedchem.6c01710

BibTeX
@article{Marx2026,
  author = {Marx, Vanessa M and Mata, Anne-Catherine and Yokokawa, Fumiaki and Kirrane, Thomas and Huang, Richard and Lakshminarayana, Suresh B and Jain, Jay Prakash and Straimer, Judith and Guiguemde, W Armand and Pei, Luying and Kulkarni, Upendra and Thompson, Christopher J and Jansen, Johanna M and Lee, Patrick S and Martin, Eric J and Polyakov, Valery R and Blaquiere, Nicole and Burckle, Alexander and Waldron, Grace and Taft, Benjamin R and Flannery, Erika L and Schulz, Hanna and Jafri, Qumber H and Chan, Katherine and Kim, Erika and Cheung, Harry and Ahyong, Vida and Lee, Changbok and Jones, Catherine L and Lunde, Christopher S and Angulo-Barturen, Iñigo and Jiménez-Díaz, María Belén and Pernaute-Lau, Leyre and Scheurer, Christian and Sax, Sibylle and Wittlin, Sergio and Campos Aguiar, Anna Caroline and Carvalho Guido, Rafael Victorio and Pereira, Dhelio B and Rosenthal, Philip J and Cooper, Roland A and Schindler, Kyra A and Fidock, David A and Campo, Brice and Campbell, Simon F and Diagana, Thierry T and Sarko, Christopher R},
  title = {Discovery of a Pyrazine-2-Carboxamide Derivative as a Potent Plasmodium falciparum Inhibitor with Potential for Single-Dose Cure},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {21},
  pages = {25712--25725},
  doi = {10.1021/acs.jmedchem.6c01710}
}
Kostenlos starten →